Joseph R. Berger, MD

Emeritus Professor of Neurology

Perelman School of Medicine

University of Pennsylvania

Tuesday, October 21, 2025

8:00 - 8:50 AM EDT

Charles T. Wethington Building, Room 127 (CTW 127)

And on Zoom: https://uky.zoom.us/j/81485627103

Upon completion of this activity, participants will be able to:

1. Describe the most recent criteria for establishing the diagnosis of MS
2. Identify classical and often diagnostic features of disorders that are frequently mistaken for multiple sclerosis
3. Discuss the reasons that physicians are led to the incorrect diagnosis of MS

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Joseph R. Berger, MD, faculty for this educational event, is a consultant for Celegene/BMS, Genentech/Roche, Gilead, Janssen/J&J, Merck, Novartis, Sandoz, Seagen, and Takeda. He was formerly a consultant for Cycle Pharma, Dice Pharmaceutical, and Morphic. Dr. Berger is a consultant/speaker for TG Therapeutics. He is also on the Scientific Advisory Board for ExcisionBio and PopulationBio.

All of the relevant financial relationships listed for this individual have been mitigated.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.